AUROBINDO PHARMA LTD (AUROPHARMA) financials

AUROBINDO PHARMA LTD (AUROPHARMA) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Market Cap: ₹95,910Cr.
Current Price: ₹1,667
Stock P/E: 36.8
ROE: 11.2%
ROCE: 13.0%
Book Value: ₹391
Dividend Yield: 0.24%
52W High / Low: ₹1,740/1,080

In Jun 2026, AUROBINDO PHARMA LTD (AUROPHARMA) reported sales ₹2,800 Cr and net profit ₹737 Cr.

Annual TTM: sales ₹11,123 Cr, net profit ₹2,593 Cr.

Shareholding: Promoters 51.88% (Sep 2026), FIIs 17.41% (Sep 2026), DIIs 24.37% (Sep 2026), Government 0.05% (Sep 2026), Public 6.29% (Sep 2026).

AUROPHARMA quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	2,825	2,917	2,732	2,848	2,790	2,747	2,787	2,800
Expenses	2,104	2,203	2,135	2,052	2,065	1,958	2,005	1,917
Operating Profit	721	713	597	796	725	789	781	882
OPM %	26%	24%	22%	28%	26%	29%	28%	32%
Other Income	123	54	114	84	160	113	214	242
Interest	52	66	61	60	57	48	47	47
Depreciation	68	68	94	70	71	72	72	69
Profit before tax	724	633	556	750	755	782	876	1,008
Tax %	26%	25%	27%	25%	23%	26%	21%	27%
Net Profit	538	472	408	559	581	582	692	737
EPS in Rs	9.25	8.13	7.03	9.63	10.01	10.02	11.92	12.81
Raw PDF	—	—	—	—	—	—	—	—

AUROPHARMA profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	13,371	15,824	11,287	8,457	10,646	10,933	11,172	11,123
Expenses	10,670	11,704	9,783	6,952	8,422	8,376	8,080	7,945
Operating Profit	2,700	4,120	1,504	1,505	2,224	2,558	3,092	3,178
OPM %	20%	26%	13%	18%	21%	23%	28%	29%
Other Income	386	590	565	429	670	328	570	728
Interest	243	29	17	75	183	230	213	200
Depreciation	473	488	415	243	255	297	285	284
Profit before tax	2,370	4,193	1,637	1,616	2,457	2,358	3,164	3,422
Tax %	21%	26%	11%	24%	20%	26%	24%	—
Net Profit	1,877	3,113	1,455	1,227	1,954	1,747	2,415	2,593
EPS in Rs	32.03	53.13	24.83	20.94	33.35	30.08	41.58	44.76
Dividend Payout %	9%	8%	36%	36%	13%	0%	10%	—

AUROPHARMA balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	59	59	59	59	59	59	58	58
Reserves	11,292	12,994	15,866	17,059	17,975	19,664	20,476	22,660
Borrowings	4,520	3,741	4,028	1,895	4,203	2,861	4,647	4,285
Other Liabilities	2,270	2,770	3,237	2,589	2,822	2,570	2,332	2,276
Total Liabilities	18,141	19,564	23,189	21,601	25,059	25,154	27,513	29,279
Fixed Assets	4,150	4,418	4,472	3,586	3,688	2,419	2,337	2,544
CWIP	789	815	735	225	239	133	88	229
Investments	2,339	2,527	5,010	6,584	8,105	13,393	15,210	17,562
Other Assets	10,863	11,804	12,972	11,206	13,027	9,209	9,879	8,945
Total Assets	18,141	19,564	23,189	21,601	25,059	25,154	27,513	29,279

AUROPHARMA cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	530	2,201	2,994	3,727	1,816	1,715	1,646	2,933
Cash from Investing Activity	-1,301	-948	-2,650	-1,615	-3,230	-152	-2,050	-1,996
Cash from Financing Activity	599	-1,255	-28	-2,448	1,719	-1,837	616	-1,072
Net Cash Flow	-171	-1	316	-335	306	-274	212	-135
Free Cash Flow	-357	1,568	2,646	3,753	1,481	1,293	1,454	2,475
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	42%	96%	88%	294%	141%	104%	91%	120%

AUROPHARMA shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.88%	51.88%
FIIs	16.29%	15.33%	14.38%	14.21%	13.95%	15.24%	16.38%	17.41%
DIIs	25.21%	26.23%	26.93%	27.60%	27.66%	25.82%	25.05%	24.37%
Government	0.00%	0.00%	0.00%	0.00%	0.03%	0.05%	0.05%	0.05%
Public	6.67%	6.61%	6.88%	6.37%	6.55%	7.08%	6.63%	6.29%
No. of Shareholders	2,57,962	2,69,323	2,72,208	2,47,662	2,36,859	2,41,298	2,39,073	2,33,737

AUROPHARMA key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	156	158	137	128	197	129	140	138
Inventory Days	235	242	244	210	335	148	154	161
Days Payable	109	107	104	104	179	112	116	125
Cash Conversion Cycle	282	293	277	234	353	166	177	174
Working Capital Days	107	132	118	181	126	65	32	27
ROCE %	15%	16%	23%	9%	8%	12%	11%	13%

AUROPHARMAUpdated 17 Oct 2026, 22:33

Aurobindo Pharma Ltd

AUROPHARMAUpdated 17 Oct 2026, 22:33

Market Cap

₹95,910Cr.

Current Price

₹1,667

High / Low

₹1,740/1,080

Stock P/E

36.8

ROE11.2%

ROCE13.0%

Book Value₹391

Face Value₹1.00

Dividend Yield0.24%

About

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	2391	32	1968	113	60	444	24	336	5.74
Sep 2023	2669	37	2124	103	66	546	24	416	7.1
Dec 2023	2692	61	2210	331	64	687	9	624	10.65
Mar 2024	2894	53	2119	123	65	780	26	579	9.88
Jun 2024	2460	51	1961	65	67	446	26	329	5.62
Sep 2024	2825	52	2104	123	68	724	26	538	9.25
Dec 2024	2917	66	2203	54	68	633	25	472	8.13
Mar 2025	2732	61	2135	114	94	556	27	408	7.03
Jun 2025	2848	60	2052	84	70	750	25	559	9.63
Sep 2025	2790	57	2065	160	71	755	23	581	10.01
Dec 2025	2747	48	1958	113	72	782	26	582	10.02
Mar 2026	2787	47	2005	214	72	876	21	692	11.92
Jun 2026	2800	47	1917	242	69	1008	27	737	12.81

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	8069	132	5816	65	245	1940	22	1516	25.96
Mar 2016	9158	229	6705	187	263	2148	24	1627	27.8
Mar 2017	9607	45	7215	118	286	2179	22	1707	29.13
Mar 2018	10270	53	7600	81	355	2343	23	1813	30.94
Mar 2019	12258	231	9838	189	413	1965	22	1530	26.11
Mar 2020	13371	243	10670	386	473	2370	21	1877	32.03
Mar 2021	15824	29	11704	590	488	4193	26	3113	53.13
Mar 2022	11287	17	9783	565	415	1637	11	1455	24.83
Mar 2023	8457	75	6952	429	243	1616	24	1227	20.94
Mar 2024	10646	183	8422	670	255	2457	20	1954	33.35
Mar 2025	10933	230	8376	328	297	2358	26	1747	30.08
Mar 2026	11172	213	8080	570	285	3164	24	2415	41.58
TTM	11123	200	7945	728	284	3422	—	2593	44.76

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	51.88%
FIIs	17.41%
DIIs	24.37%
Government	0.05%
Public	6.29%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Dec 2023	51.84%	20.72%	20.6%	0%	6.85%
Mar 2024	51.84%	18.01%	23.28%	0%	6.87%
Jun 2024	51.8%	16.73%	24.77%	0%	6.69%
Sep 2024	51.82%	16.59%	25.14%	0%	6.45%
Dec 2024	51.82%	16.29%	25.21%	0%	6.67%
Mar 2025	51.82%	15.33%	26.23%	0%	6.61%
Jun 2025	51.82%	14.38%	26.93%	0%	6.88%
Sep 2025	51.82%	14.21%	27.6%	0%	6.37%
Dec 2025	51.82%	13.95%	27.66%	0.03%	6.55%
Mar 2026	51.82%	15.24%	25.82%	0.05%	7.08%
Jun 2026	51.88%	16.38%	25.05%	0.05%	6.63%
Sep 2026	51.88%	17.41%	24.37%	0.05%	6.29%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	29	5330	3285	1582	10226	2190	227	1013	6796	10226
Mar 2016	59	6807	4165	1534	12566	2568	742	1183	8072	12566
Mar 2017	59	8378	3054	1533	13023	3212	907	1682	7222	13023
Mar 2018	59	9924	3719	2092	15794	3393	1144	1968	9289	15794
Mar 2019	59	11292	4520	2270	18141	4150	789	2339	10863	18141
Mar 2020	59	12994	3741	2770	19564	4418	815	2527	11804	19564
Mar 2021	59	15866	4028	3237	23189	4472	735	5010	12972	23189
Mar 2022	59	17059	1895	2589	21601	3586	225	6584	11206	21601
Mar 2023	59	17975	4203	2822	25059	3688	239	8105	13027	25059
Mar 2024	59	19664	2861	2570	25154	2419	133	13393	9209	25154
Mar 2025	58	20476	4647	2332	27513	2337	88	15210	9879	27513
Mar 2026	58	22660	4285	2276	29279	2544	229	17562	8945	29279

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	590	-624	35	1
Mar 2016	1185	-1390	515	310
Mar 2017	2457	-1542	-1329	-414
Mar 2018	922	-991	440	371
Mar 2019	530	-1301	599	-171
Mar 2020	2201	-948	-1255	-1
Mar 2021	2994	-2650	-28	316
Mar 2022	3727	-1615	-2448	-335
Mar 2023	1816	-3230	1719	306
Mar 2024	1715	-152	-1837	-274
Mar 2025	1646	-2050	616	212
Mar 2026	2933	-1996	-1072	-135

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	168	175	143	159	156	158	137	128	197	129	140	138
Inventory Days	207	207	191	273	235	242	244	210	335	148	154	161
Days Payable	111	109	96	130	109	107	104	104	179	112	116	125
Cash Conversion Cycle	264	273	239	301	282	293	277	234	353	166	177	174
Working Capital Days	108	84	92	106	107	132	118	181	126	65	32	27
ROCE %	27%	24%	20%	19%	15%	16%	23%	9%	8%	12%	11%	13%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of AUROBINDO PHARMA LTD (AUROPHARMA)?

The reported market capitalisation for AUROBINDO PHARMA LTD (AUROPHARMA) is ₹95,910Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of AUROPHARMA?

The current price shown for AUROBINDO PHARMA LTD (AUROPHARMA) on Fincrux is ₹1,667 with a 52-week high/low of ₹1,740/1,080.

What is the P/E ratio of AUROBINDO PHARMA LTD (AUROPHARMA)?

The stock P/E for AUROBINDO PHARMA LTD (AUROPHARMA) is 36.8 on Fincrux, with ROE at 11.2% and ROCE at 13.0%.

What were AUROPHARMA latest quarterly results?

For Jun 2026, AUROBINDO PHARMA LTD (AUROPHARMA) reported sales ₹2,800 Cr and net profit ₹737 Cr (figures in ₹ crore unless noted).

What are AUROPHARMA annual sales and net profit?

For TTM, AUROBINDO PHARMA LTD (AUROPHARMA) shows sales of ₹11,123 Cr and net profit of ₹2,593 Cr on the Fincrux profit & loss statement.

Who owns AUROBINDO PHARMA LTD (AUROPHARMA)?

Latest shareholding for AUROBINDO PHARMA LTD (AUROPHARMA) on Fincrux: Promoters 51.88% (Sep 2026), FIIs 17.41% (Sep 2026), DIIs 24.37% (Sep 2026), Government 0.05% (Sep 2026), Public 6.29% (Sep 2026).

Where can I find AUROBINDO PHARMA LTD (AUROPHARMA) financials?

AUROBINDO PHARMA LTD (AUROPHARMA) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show AUROPHARMA balance sheet and cash flow?

Yes. The AUROBINDO PHARMA LTD (AUROPHARMA) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 17 October 2026 at 22:33